Compare VTSI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | LUNG |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 57.9M |
| IPO Year | 1999 | 2020 |
| Metric | VTSI | LUNG |
|---|---|---|
| Price | $3.20 | $1.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $5.38 |
| AVG Volume (30 Days) | 52.3K | ★ 349.1K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $185,971.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $27.30 | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $3.16 | $1.13 |
| 52 Week High | $7.47 | $3.88 |
| Indicator | VTSI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 47.30 |
| Support Level | N/A | $1.20 |
| Resistance Level | $3.60 | $1.45 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 3.48 | 33.33 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.